Abstract 459P
Background
Lung cancer is the most frequently diagnosed cancer and the leading cause of cancer death among males and females. There is evidence that diet habit may influence lung cancer risk. To determine the association between fish intake and dietary polyunsaturated fatty acids (PUFA) and incidence of lung cancer, we identified all available studies to clarify the dose-response relationship between fish and PUFA and lung cancer risk, evaluated the potential effects of frequent fish and PUFA intake on lung cancer mortality, and studied the ability of their supplementations during chemotherapy in patients with lung cancer.
Methods
We systematically reviewed and meta-analyzed the published studies in MEDLINE, EMBASE databases, Cochrane Library database (Cochrane central register of controlled trials) and ClinicalTrials, supplemented with manual screening. Large-scale prospective cohort study and randomized control trials quantifying the associations of fish and PUFA consumption with risk of lung cancer were included. Two investigators dependently assessed studies for inclusion and extracted data on methods, interventions, outcomes and study quality. Relative risk (RR) with 95% confidence interval (CI) was calculated.
Results
13 population-based prospective cohort studies involving 1,785,000 participants and 2 randomized control trials were included. Our study demonstrated that dietary PUFA significant reduced risk of lung cancer for men (RR 0.99, 95%CI 0.98 to 1.00) and USA population (RR 0.99, 95%CI 0.98 to 1.00). Dose-response analysis indicated that a 5g/day increment of dietary PUFA was associated with 5% lower risk of lung cancer (RR 0.95, 95%CI 0.91 to 0.99). In addition, PUFA supplementation is significant improved overall survival in patients with lung cancer (RR 1.98, 95%CI 1.09 to 3.59).
Conclusions
Our study showed an inverse association between dietary PUFA and risk of lung cancer in males and among USA population. Although smoking cessation is the single biggest factor associated with lung cancer risk reduction, this study adds to a growing body of evidence that diet may have a role in modestly reducing lung cancer risk.
Clinical trial identification
Editorial acknowledgement
This work was supported by program for the National Natural Science Foundation of China (grant number 81700025), the Medical and Health Science and Technology Project of Zhejiang (grant number 2018245859), the Medical Science and Technology Plan Projects of Ningbo (grant number 2016A03), the Science Foundation of Zhejiang (grant number LY15H010002) and the Beijing Medical Health Foundation (grant number YWJKJJHKYJJ-HX32).
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
220P - An outcome analysis of robotassisted radical nephroureterectomy with extended template lymphadenectomy for upper tract urothelial carcinoma
Presenter: Ashwin Tamhankar
Session: Poster display session
Resources:
Abstract
221P - Comparative analysis of first-line immune checkpoint inhibitor versus carboplatin-based chemotherapy for cisplatin-ineligible metastatic urothelial carcinoma: A multicenter, retrospective real-world evidence
Presenter: Hsiang‐Lan Lai
Session: Poster display session
Resources:
Abstract
222P - Does tumor grade really improve the prognostic ability of the staging system for men with penile cancer: A SEER database analysis
Presenter: Ravi Kanodia
Session: Poster display session
Resources:
Abstract
223TiP - EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma
Presenter: Daniel Petrylak
Session: Poster display session
Resources:
Abstract
230P - Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort
Presenter: Lingying Wu
Session: Poster display session
Resources:
Abstract
231P - Cost-effectiveness of olaparib vs routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore
Presenter: David SP Tan
Session: Poster display session
Resources:
Abstract
233P - Incorporation of correlative studies in ovarian cancers in the era of precision medicine: Assessment of accountability and utility
Presenter: Nadia Hitchen
Session: Poster display session
Resources:
Abstract
234P - Implementation of mainstream BRCA testing in epithelial ovarian cancer in a tertiary centre
Presenter: Edbert Wong
Session: Poster display session
Resources:
Abstract
235P - The efficacy of radiation therapy in ovarian carcinoma: A propensity score analysis of a population-based study
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
236P - Front-line maintenance therapy for platinum-sensitive ovarian cancer: What’s next PARP inhibitors?
Presenter: Han Gong
Session: Poster display session
Resources:
Abstract